Melanie Newman
Family · Hot Springs, ARNPI 1598705634
Payments from drug & device makers
Across 40 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$83
- AbbVie$67
- Sanofi Pasteur Inc.$49
- Gilead$44
- Viiv Healthcare Company$44
- Novo Nordisk$44
- plus $431 from 19 others
What the payments were for
- Food & beverage$761100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 5 | $83 |
| AbbVie | 2 | $67 |
| Sanofi Pasteur Inc. | 3 | $49 |
| Gilead | 2 | $44 |
| Viiv Healthcare Company | 2 | $44 |
| Novo Nordisk | 3 | $44 |
| Amgen | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Shield Therapeutics Inc | 2 | $36 |
| Corium, LLC | 2 | $36 |
| Ferring Pharmaceuticals Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $24 |
| Pacira Therapeutics, Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Vertex | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Convatec Inc. | 1 | $14 |
| Tonix Medicines, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
How this compares
$761 in reported general payments places this provider in the 60th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 25 | $21,814 |
| OzempicSemaglutide | 17 | $16,199 |
| EliquisApixaban | 25 | $12,764 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $10,487 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $8,994 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,018 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,479 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 172 | $3,823 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $3,238 |
| Gabapentin | 186 | $2,245 |
| Omeprazole | 120 | $2,108 |
| Atorvastatin Calcium | 198 | $1,217 |
| ValacyclovirValacyclovir Hcl | 24 | $1,141 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,124 |
| Doxepin Hcl | 19 | $1,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $17 | $24,98342 claims |
| Novo NordiskOzempic | $44 | $16,19917 claims |
| PfizerEliquis | $19 | $12,76425 claims |
| AbbVieSynthroid | $67 | $50911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,103 family providers in Arkansas.
Other family in Hot Springs
- Kayla StanageHot Springs$10K
- Robert McDanielsHot Springs$9K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.